Eli Lilly and Company $LLY Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,424,027 shares of the company’s stock after purchasing an additional 360,511 shares during the quarter. Eli Lilly and Company comprises 1.8% of Fisher Asset Management LLC’s holdings, making the stock its 13th largest position. Fisher Asset Management LLC owned approximately 0.58% of Eli Lilly and Company worth $6,276,034,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Coastal Bridge Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $2,959,000. Birinyi Associates Inc. boosted its holdings in Eli Lilly and Company by 32.6% during the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after buying an additional 359 shares in the last quarter. Mosaic Family Wealth Partners LLC grew its position in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after buying an additional 1,430 shares during the period. Heritage Investors Management Corp grew its position in shares of Eli Lilly and Company by 6.5% during the 3rd quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock valued at $13,624,000 after acquiring an additional 718 shares during the period. Finally, Canton Hathaway LLC grew its position in shares of Eli Lilly and Company by 160.4% during the 3rd quarter. Canton Hathaway LLC now owns 2,273 shares of the company’s stock valued at $2,630,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Investors following LLY have been watching these news items:

• Positive Sentiment: China approved orforglipron, making Lilly the first company with an approved GLP-1 weight-loss pill in the country. The approval gives LLY a route into a large obesity-treatment market and a potential edge while rival oral treatments await regulatory decisions. Reuters article
• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania facility to make injectable medicines, including next-generation candidate retatrutide. The investment could expand manufacturing capacity for future demand and is expected to create 850 permanent jobs, though the benefits will take time to materialize. Lilly facility announcement
• Positive Sentiment: A Phase 3b study found that combining Zepbound with Taltz improved and sustained outcomes in adults with psoriatic arthritis and obesity compared with Taltz alone. The results could support broader use of Lilly’s medicines in patients with both conditions. Phase 3b study announcement

Eli Lilly and Company Stock Down 0.3%

Shares of NYSE LLY opened at $1,433.34 on Friday. The firm has a market cap of $1.35 trillion, a price-to-earnings ratio of 46.52, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40. The company’s 50-day simple moving average is $1,236.58 and its 200-day simple moving average is $1,108.27. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,460.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. BMO Capital Markets reissued an “outperform” rating and issued a $1,650.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. HSBC boosted their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Morgan Stanley upped their target price on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Insider Activity at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.